RecruitingEarly Phase 1NCT06424301

Targeting NUDT21 siRNA Drugs for Patients With Refractory Retinoblastoma

Studying Hereditary retinoblastoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Eye & ENT Hospital of Fudan University
Principal Investigator
Chen Zhao, MD
Fudan Eye & ENT Hospital
Intervention
Targeting NUDT21 siRNA drugs(drug)
Enrollment
2 enrolled
Eligibility
All sexes
Timeline
2024 – 2025

Study locations (1)

Collaborators

The Eye Hospital of Wenzhou Medical University

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06424301 on ClinicalTrials.gov

Other trials for Hereditary retinoblastoma

Additional recruiting or active studies for the same condition.

See all trials for Hereditary retinoblastoma →

← Back to all trials